JP2015512866A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512866A5
JP2015512866A5 JP2014552368A JP2014552368A JP2015512866A5 JP 2015512866 A5 JP2015512866 A5 JP 2015512866A5 JP 2014552368 A JP2014552368 A JP 2014552368A JP 2014552368 A JP2014552368 A JP 2014552368A JP 2015512866 A5 JP2015512866 A5 JP 2015512866A5
Authority
JP
Japan
Prior art keywords
seq
cancer
vaccine
cell
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014552368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512866A (ja
JP6282598B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/021448 external-priority patent/WO2013106834A2/en
Publication of JP2015512866A publication Critical patent/JP2015512866A/ja
Publication of JP2015512866A5 publication Critical patent/JP2015512866A5/ja
Application granted granted Critical
Publication of JP6282598B2 publication Critical patent/JP6282598B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014552368A 2012-01-13 2013-01-14 免疫原性ｗｔ１ペプチド及びその使用方法 Expired - Fee Related JP6282598B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261586177P 2012-01-13 2012-01-13
US61/586,177 2012-01-13
US201261647207P 2012-05-15 2012-05-15
US61/647,207 2012-05-15
PCT/US2013/021448 WO2013106834A2 (en) 2012-01-13 2013-01-14 Immunogenic wt-1 peptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018009786A Division JP6995645B2 (ja) 2012-01-13 2018-01-24 免疫原性ｗｔ１ペプチド及びその使用方法

Publications (3)

Publication Number Publication Date
JP2015512866A JP2015512866A (ja) 2015-04-30
JP2015512866A5 true JP2015512866A5 (enExample) 2016-02-25
JP6282598B2 JP6282598B2 (ja) 2018-02-21

Family

ID=48782099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014552368A Expired - Fee Related JP6282598B2 (ja) 2012-01-13 2013-01-14 免疫原性ｗｔ１ペプチド及びその使用方法
JP2018009786A Active JP6995645B2 (ja) 2012-01-13 2018-01-24 免疫原性ｗｔ１ペプチド及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018009786A Active JP6995645B2 (ja) 2012-01-13 2018-01-24 免疫原性ｗｔ１ペプチド及びその使用方法

Country Status (8)

Country Link
US (3) US20150104413A1 (enExample)
EP (2) EP3520810A3 (enExample)
JP (2) JP6282598B2 (enExample)
CN (2) CN104684577B (enExample)
AU (2) AU2013207669C1 (enExample)
CA (1) CA2861206C (enExample)
HK (1) HK1204261A1 (enExample)
WO (1) WO2013106834A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
US10048271B2 (en) 2012-12-11 2018-08-14 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
PL2931304T3 (pl) * 2012-12-13 2021-11-08 The Trustees Of The University Of Pennsylvania Szczepionka wt1
JP7025119B2 (ja) * 2014-04-24 2022-02-24 ロード アイランド ホスピタル アスパラギン酸－β－ヒドロキシラーゼは腫瘍においてエピトープ特異的Ｔ細胞応答を誘導する
WO2016208332A1 (ja) * 2015-06-25 2016-12-29 国立大学法人神戸大学 経口腫瘍ワクチン
CA2997757A1 (en) * 2015-09-10 2017-03-16 Memorial Sloan Kettering Cancer Center Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy
EP3362929B1 (en) 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
SMT202200370T1 (it) * 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
JP6609724B1 (ja) 2017-01-06 2019-11-20 ユーティレックス カンパニー リミテッド 抗ヒト４−１ｂｂ抗体およびその使用
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
CN111655714A (zh) * 2017-11-08 2020-09-11 阿德瓦希斯公司 来自癌症相关蛋白的免疫原性异变肽及其使用方法
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
MX2020012649A (es) * 2018-05-25 2021-07-02 The Wistar Inst Neoantígenos especificos de tumor y métodos de uso de estos.
WO2020132366A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
CN110423723A (zh) * 2019-07-18 2019-11-08 南方医科大学南方医院 一种外周血b细胞系的构建方法及其应用
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA8748A (en) 1878-05-04 George W. Ainsworth Improvements on clothes dryers
CA23766A (en) 1886-04-06 Albert M. Todd Process of, and appartus for treating essential oils to obtain the concrete or crystalline part thereof separate and apart from the liquid portion
CA59350A (en) 1898-02-26 1898-03-19 Thomas Henry Simmonds Brake for velocipede, tricycle, etc.
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1994021287A1 (en) 1993-03-15 1994-09-29 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Peptide coated dendritic cells as immunogens
AU2392795A (en) 1994-04-22 1995-11-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Isolation and characterization of a novel primate t-cell lymphotropic virus and the use of this virus or components thereof in diagnostics assays and vaccines
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6156316A (en) 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
JPH11171896A (ja) 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US5981217A (en) 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6207375B1 (en) 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
HK1038929B (zh) 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20120301492A1 (en) 1998-09-30 2012-11-29 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1144444A3 (en) 1998-12-22 2002-01-02 Genset Dnas encoding proteins with signal sequences
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU3755800A (en) 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
US6593299B1 (en) * 1999-04-21 2003-07-15 University Of Florida Research Foundation, Inc. Compositions and methods for controlling pests
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1209226A3 (en) 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
DE60238958D1 (de) 2001-06-29 2011-02-24 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US20050008618A1 (en) 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
EP2463299A3 (en) * 2003-03-05 2012-10-17 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
CA2530184C (en) 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
EP2478913A1 (en) 2003-12-01 2012-07-25 Sloan-Kettering Institute For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
ES2484340T3 (es) 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
WO2005087260A1 (en) 2004-03-04 2005-09-22 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
US20050214268A1 (en) 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
JP4886507B2 (ja) 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
US20120052080A1 (en) 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US9629927B2 (en) 2005-07-29 2017-04-25 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses thereof
CA2626238C (en) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2352855T3 (es) * 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
CN102250211A (zh) 2006-02-22 2011-11-23 株式会社癌免疫研究所 Hla-a*3303限制性wt1肽和包含此肽的药物组合物
WO2007119564A1 (ja) 2006-03-29 2007-10-25 International Institute Of Cancer Immunology, Inc. ＷＴ１ １７ＡＡ（－）アイソフォーム特異的ｓｉＲＮＡおよびその利用
WO2007120603A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic bcr-abl peptides and methods of use thereof
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
CA2886621A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
JP5239041B2 (ja) 2007-02-07 2013-07-17 一般財団法人阪大微生物病研究会 癌の治療剤
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
KR101238795B1 (ko) 2007-05-24 2013-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
KR100995340B1 (ko) 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
JP5478260B2 (ja) 2007-12-05 2014-04-23 株式会社癌免疫研究所 癌ワクチン組成物
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
US20130288236A1 (en) 2009-11-11 2013-10-31 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
KR20140022836A (ko) 2011-03-11 2014-02-25 길리아드 칼리스토가 엘엘씨 혈액 악성종양에 대한 조합 요법
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
US9783821B2 (en) 2011-07-29 2017-10-10 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US9539299B2 (en) 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
US20140341939A1 (en) 2011-12-14 2014-11-20 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
ES2655031T3 (es) 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
US9226955B2 (en) 2012-10-23 2016-01-05 Ubivac, Llc Allogeneic autophagosome-enriched composition for the treatment of disease
EA201591168A1 (ru) 2012-12-17 2016-05-31 Оцука Фармасьютикал Ко., Лтд. Способ активации хелперной t-клетки
CN104968782B (zh) 2012-12-26 2019-09-06 生物科莫公司 利用人副流感2型病毒载体的疫苗
CN110078813B (zh) 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
IN2014CH00391A (enExample) 2013-02-05 2015-04-03 Nitto Denko Corp
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
RU2697443C2 (ru) 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
WO2014144885A2 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
EP2982681B8 (en) 2013-03-29 2018-11-07 Sumitomo Dainippon Pharma Co., Ltd. Wt1-antigen peptide conjugate vaccine
SI2988762T1 (sl) 2013-04-25 2018-10-30 Vaximm Ag Vektorji na osnovi salmonele za imunoterapijo raka, usmerjeno v Wilmsov tumorski gen WT1
CA2912514A1 (en) 2013-05-13 2014-11-20 International Institute Of Cancer Immunology, Inc. Method for predicting clinical effect of immunotherapy
JP6406647B2 (ja) 2013-07-02 2018-10-17 公益財団法人がん研究会 細胞性免疫誘導ワクチン
EP3071594A4 (en) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
JP6662787B2 (ja) 2013-12-18 2020-03-11 バキシム ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌免疫療法のための新規ｍｓｌｎ標的化ｄｎａワクチン
CA3156357A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
WO2015123496A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
US10253075B2 (en) 2014-02-26 2019-04-09 tella, Inc. WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
US10023841B2 (en) 2014-05-23 2018-07-17 Baylor Research Institute Methods and compositions for treating breast cancer with dendritic cell vaccines
HK1251184A1 (zh) 2014-12-11 2019-01-25 International Institute Of Cancer Immunology, Inc. 血管生成性疾病的免疫疗法
WO2016208332A1 (ja) 2015-06-25 2016-12-29 国立大学法人神戸大学 経口腫瘍ワクチン
WO2017049074A1 (en) 2015-09-18 2017-03-23 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases

Similar Documents

Publication Publication Date Title
Molino et al. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses
Berger et al. Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma
Greiner et al. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens
CN103502439B (zh) 用于抗原特异性t细胞增殖的方法
Diken et al. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA
CN104087592B (zh) Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途
JP2010514455A5 (enExample)
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Talesh et al. Poly (I: C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model
JP2014514927A5 (enExample)
WO2010016525A1 (ja) 免疫誘導剤
Nguyen-Pham et al. Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma
JP2019517544A5 (enExample)
Proietti et al. Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy
Nijman et al. Immunologic aspect of ovarian cancer and p53 as tumor antigen
JP2018528960A5 (enExample)
CN104262459A (zh) 一种急性单核细胞白血病相关抗原mlaa-34 表位多肽及其疫苗和制药应用
JP4780540B2 (ja) サバイビン由来癌抗原ペプチド
US20170100438A1 (en) Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy
Tüting T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients
JP2008523067A (ja) 癌ワクチンアジュバントとしてのαサイモシンペプチド
WO2017161950A1 (zh) 皮氨钙联合佐剂及含有皮氨钙联合佐剂的疫苗
Ho et al. Immunotherapy for lung cancers
US20200297829A1 (en) Integrative Immunotherapy for Cancer Treatment
US20160235827A1 (en) Placental compositions for stimulation of immunity to pd-l1